Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 12, 2010, Pages 1876-1882

  An, Ho Jung ^a   Jang, Jeong Won ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Cho, Se Hyun ^a   Yoon, Seung Kew ^a   Han, June Yeol ^a   Lee, Keun Ho ^a   Kim, Dong Goo ^a   Jung, Eun Sun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Hepatectomy; Hepatitis B virus; Hepatocellular carcinoma; Recurrence; Viral load

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; TUMOR VOLUME; VIRUS LOAD; VIRUS REPLICATION;

EID: 78649554818     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06416.x     Document Type: Article

References (26)

1. Kim SY. Deaths and Causes of Death in 2007: STATISTICS KOREA [Internet]. Korea: National Statistical Office; 2008 Sep 23. Cited 14 June 2010. Available from URL:
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
3. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg. 2009; 249: 20-5.
4. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991; 14: 802-5.
5. Adachi E, Maeda T, Matsumata T et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108: 768-75.
6. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
7. Kubo S, Hirohashi K, Tanaka H et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-24.
8. Kubo S, Hirohashi K, Tanaka H et al. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig. Surg. 2001; 18: 26-33.
9. Ohkubo K, Kato Y, Ichikawa T et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 2663-8.
10. Kim BK, Park JY, Kim Y et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008; 28: 393-401.
11. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 1663-73.
12. Chuma M, Hige S, Kamiyama T et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 2009; 44: 991-9.
13. Kang SH, Park YM, Choi JY et al. Lamivudine-resistance in patients with chronic hepatitis B and/or cirrhosis and detection of mutations in YMDD motif of hepatitis B virus genome. Korean J. Hepatol. 2001; 7: 15-33.
14. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954; 7: 462-503.
15. Kubo S, Tanaka H, Takemura S et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol. Res. 2007; 37: 94-100.
16. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J. Gastroenterol. 2007; 13:74-81.
17. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007; 252: 157-70.
18. Pan J, Clayton M, Feitelson MA. Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J. Gen. Virol. 2004; 85: 275-82.
19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
20. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
21. Yoon YJ, Chang HY, Ahn SH et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-6.
22. Hino O, Kajino K. Hepatitis virus-related hepatocarcinogenesis. Intervirology 1994; 37: 133-5.
23. Volpes R, Van Den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 59-65.
24. Kumada T, Nakano S, Takeda I et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
25. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cells 2006; 10: 99-111.
26. Wu JC, Huang YH, Chau GY et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J. Hepatol. 2009; 51: 890-7.